Aedicell is a regenerative medicine company that has developed a unique proprietary process to transform human tissue into biologics for therapy. Our focus is on the conversion of human placenta into our skin substitute products Plurivest and Dermavest.
Our Mission and Strategic Intent
Aedicell’s mission is to deliver wound therapies for superior outcomes at a lower cost to the healthcare system by using rapid, advanced product development and manufacturing techniques.
This strategy enables Aedicell to compete not just in the end-care, advanced product/pricing segment, but also earlier in the treatment algorithm where we can address a much larger patient population.